A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Clinical trial NCT04982237 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04982237
- Sponsor
- Akeso
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-27
- Primary completion
- 2025-12-30
- Enrollment
- 445
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.